文献速递临床试验与 GCP医学教育与科研方法

主要临床试验注册平台对上市后临床试验所用已批准药物的质量保证信息字段稀缺

Scarce quality assurance documentation in major clinical trial registries for approved medicines used in post-marketing clinical trials.
PubMed 文献 · Trials · 2019-04-11

该研究由两名评价者独立评估了国际医学期刊编辑委员会(ICJME)与世界卫生组织(WHO)平台下的临床试验注册平台(CTR),检查其是否设有关于已批准药物作为研究用药品(IMP)用于IV期临床试验时的质量保证字段。在19个注册平台中,仅欧盟CTR设有生产商名称、批准状态和批准机构字段,所有注册平台均未设置药品生产质量管理规范符合性和质量检测字段。作者认为应弥补质量保证字段的缺口,并在相关措施实施前,在缺乏严格监管能力的国家开展IV期临床试验时优先选择欧盟CTR进行注册。

要点

  • 在19个注册平台中,仅欧盟CTR设有生产商名称、批准状态和批准机构字段。
  • 所有注册平台均未设置药品生产质量管理规范符合性和质量检测字段。
  • 作者建议应弥补质量保证字段的缺口,并同步调整WHO和ICJME的注册平台指南。

核心结论

  • 本研究表明,ICJME和WHO平台下的注册平台均没有足够字段来确认上市后研究用药品的来源具有质量保证。
  • 鉴于WHO和ICJME指南有冗长要求,这一结果令人惊讶。
  • 考虑到研究用药品质量与临床试验参与者安全之间的关系,应同步弥补注册平台的质量保证字段缺口并调整WHO和ICJME关于注册平台的指南。
  • 具体而言,应在临床试验开展前、中、后对研究用药品进行质量检测并报告,检测应涵盖外观、杂质、微生物污染和给药剂量等问题。
  • 在这些措施被采纳之前,在缺乏严格监管能力的国家开展IV期临床试验时,应优先选择欧盟CTR进行注册。

研究设计与样本

  • 两名评价者独立评估了国际医学期刊编辑委员会(ICJME)和世界卫生组织(WHO)平台下的临床试验注册平台(CTR)。
  • 每名评价者检查每个CTR是否设有以下字段:品牌名称、生产商名称、批准状态、批准机构、药品生产质量管理规范符合性以及质量检测。
  • 评价者意见不一致时,通过两名评价者协商达成共识。

主要发现

  • 共识别出19个CTR,其中8个属于WHO平台,6个属于ICJME平台,5个同时属于两个平台。
  • 所有CTR均设有「干预」字段,用于采集研究用药品及其对照品的数据。
  • 加拿大CTR使用「药品名称」而非「干预」字段。
  • 欧盟、秘鲁和英国CTR设有「品牌名称」字段。
  • 仅欧盟CTR设有「生产商名称」、「批准状态」和「批准机构」字段。

临床怎么用

  • 作者建议应同步弥补注册平台的质量保证字段缺口并调整WHO和ICJME关于注册平台的指南。
  • 作者建议应在临床试验开展前、中、后对研究用药品进行质量检测并报告,检测应涵盖外观、杂质、微生物污染和给药剂量等问题。
  • 作者认为,在这些措施被采纳之前,在缺乏严格监管能力的国家开展IV期临床试验时,应优先选择欧盟CTR进行注册。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: This research reviewed major Clinical Trial Registries (CTRs) and assessed the availability of fields on quality assurance for approved medicines used as Investigational Medicinal Products (IMPs) in phase IV clinical trials. METHODS: Two reviewers independently assessed CTRs of the International Committee of Medical Journal Editors (ICJME) and of World Health Organization (WHO) platforms. Each CTR was checked by two reviewers on availability of fields on brand name, manufacturer's name, approval status, approving authority, compliance with Good Manufacturing Practices, and quality testing. In case of discrepancy, consensus was sought between the two reviewers. RESULTS: Of 19 identified CTRs, 8 and 6 belonged to WHO and ICMJE, respectively, while 5 were equally part of both platforms. All CTRs had an 'intervention' field where data on IMPs and IMP comparators are captured. The Canadian CTR used 'drug name' rather than 'intervention'. The EU, Peruvian, and UK CTRs had fields for 'brand name'. However, only the EU CTR had fields for 'manufacturer's name', 'approval status', and 'approving authority'. None of the CTRs had fields on 'compliance with Good Manufacturing Practices' or 'quality testing'. CONCLUSION: This study demonstrates that none of the CTRs of ICMJE and WHO platforms has adequate fields to establish that the source of post-marketing IMPs is of assured quality. This is astonishing given the lengthy requirements in WHO and ICMJE guidelines. Considering the relation between IMP quality and safety of clinical trial participants, the gap of quality assurance fields should be bridged at CTRs concurrently to adjustments of WHO and ICMJE guidelines on CTRs. Specifically, IMP quality testing addressing issues on IMP appearance, impurities, microbial contamination, and dosing should be conducted and reported before, during, and after clinical trial conduct. Until adoption of these measures, the EU CTR should be preferred for registration of phase IV clinical trials conducted in countries lacking stringent regulatory capacities.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Doua YJ, Dominicus H, Mugwagwa J, et al. Scarce quality assurance documentation in major clinical trial registries for approved medicines used in post-marketing clinical trials. Trials. 2019. PMID: 30975193. doi:10.1186/s13063-019-3277-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。